EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Long-acting intranasal insulin for the treatment of delirium—a randomised clinical trial

Anita Nitchingham iD, Jacqueline C T Close iD, Lara Ann Harvey iD, Morag E Taylor, Peter Humburg, Bernard Tuch, Meera Agar iD, Gideon A Caplan

Age and Ageing · 2025

DOI: 10.1093/ageing/afaf276 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, 2025. Verfasst von Anita Nitchingham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Randwick Clinical Campus, University of New South Wales, Randwick, NSW, Australia. Hauptthemen laut MEDLINE: Delirium, Insulin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JJ Mason & HS Williams Memorial Fund, The Julia Lowy Foundation, Harry Triguboff Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Delirium affects up to 25% of hospitalised older patients; however, there are no effective pharmacological treatments. Accumulating evidence of brain insulin resistance and altered cerebral glucose metabolism during delirium present a promising therapeutic target.

Objective

To assess the safety and efficacy of intranasal insulin in the treatment of delirium.

Design

Single-centre, randomised, double-blind, placebo-controlled trial.

Setting

Two geriatric medicine wards in a tertiary hospital.

Participants

100 patients aged over 64 years presenting to hospital and admitted under geriatric medicine with delirium.

Interventions

Participants were randomised in a 1:1 ratio to receive 20 IU of long-acting insulin or placebo intranasally twice daily until delirium resolution, hospital discharge or intervention futility defined by prespecified criteria. Main outcome The primary outcome was delirium duration, assessed daily using the Confusion Assessment Method. Secondary outcomes included acute length of stay (LOS), delirium severity, antipsychotic use, hospital complications and mortality.

Results

The intention-to-treat analysis included 97 participants [intranasal insulin n = 48, control n = 49; mean (SD) age, 87.6 (7.0) years; 63% female]. Baseline characteristics were similar between groups. Median delirium duration [days (IQR)] was 4.8 [2.9, 9.2] for intranasal insulin and 6.8 [4.0, 9.8] for the control (HR 0.7, 95% CI 0.43–1.15; P = .16). Median acute LOS (days) was 7.9 [4.6, 14.5] for intranasal insulin and 12.9 [6.9, 16.8] for the control (HR 0.56, 0.35–0.89; P = .014). No significant differences were observed in other secondary outcomes. Intranasal insulin demonstrated favourable tolerability. Overall, 86% of the participants were compliant with the intervention (≥80% of doses). Prespecified subgroup analysis revealed an age-related response, with participants aged ≤88 years showing shorter delirium duration with intranasal insulin [n = 46; intranasal insulin: median 3.9 (IQR 2.9, 6.9) days vs control: 7.0 (4.7, 9.7); HR 0.34, 0.16–0.74; P = .006], whereas no difference was observed in participants aged >88 years [n = 51; intranasal insulin 5.4 (2.9, 11.1) vs control 4.9 (2.6, 12.9); HR 0.87, 0.39–1.94; P = .73]. Conclusion and relevance This is the first study of intranasal insulin for delirium treatment. The reduced LOS combined with the observed age-related effects warrants further investigation into the clinical potential of intranasal insulin in managing delirium in older patients.

Trial registration

ACTRN 12618000318280.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeliriumInsulinHumansFemaleAdministration, IntranasalMaleDouble-Blind MethodAgedAged, 80 and overTreatment OutcomeLength of StayTime FactorsTertiary Care CentersAntipsychotic AgentsIntention to Treat AnalysisMiddle AgedAge Factors

Stichwörter der Autor:innen

deliriumgeriatricsintranasal insulinolder peoplepharmacologicaltreatment

Substanzen

InsulinAntipsychotic Agents

Autor:innen und Institutionen

  • Randwick Clinical Campus, University of New South Wales, Randwick, NSW, Australia.
  • Department of Geriatric Medicine, Prince of Wales Hospital and Community Health Services, Randwick, NSW, Australia.
  • Falls, Balance and Injury Research Centre, Neuroscience Research Australia, Randwick, NSW, Australia.
  • School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia.
  • School of Health Sciences, University of New South Wales, Sydney, NSW, Australia.
  • Ageing Futures Institute, University of New South Wales, Sydney, NSW, Australia.

ORCID-Profile: Anita Nitchingham, Jacqueline C T Close, Lara Ann Harvey, Meera Agar

Förderung

  • JJ Mason & HS Williams Memorial Fund
  • The Julia Lowy Foundation
  • Harry Triguboff Foundation

Zitieren

APA

Nitchingham, A., Close, J. C. T., Harvey, L. A., Taylor, M. E., Humburg, P., Tuch, B., Agar, M., & Caplan, G. A. (2025). Long-acting intranasal insulin for the treatment of delirium—a randomised clinical trial. Age and Ageing. https://doi.org/10.1093/ageing/afaf276

Vancouver

Nitchingham A, Close JCT, Harvey LA, Taylor ME, Humburg P, Tuch B, et al. Long-acting intranasal insulin for the treatment of delirium—a randomised clinical trial. Age and Ageing. 2025. doi:10.1093/ageing/afaf276

BibTeX
@article{Nitchingham2025,
  author = {Nitchingham, Anita and Close, Jacqueline C T and Harvey, Lara Ann and Taylor, Morag E and Humburg, Peter and Tuch, Bernard and Agar, Meera and Caplan, Gideon A},
  title = {Long-acting intranasal insulin for the treatment of delirium—a randomised clinical trial},
  journal = {Age and Ageing},
  year = {2025},
  doi = {10.1093/ageing/afaf276}
}
Kostenlos starten →